ERBB2 and triple-negative breast carcinoma: The achievement of pCR is associated with improved long-term outcomes, particularly among patients with triple-negative breast cancer or Human Epidermal Growth Factor Receptor 2 positive/hormone-receptor-negative (HER2+/HR-) tumors [13].